# Synlogic Inc. (SYBX)

Source: https://www.quantisnow.com/company/SYBX
Generated: 2026-11-19T07:40:13.289Z

- Ticker: SYBX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- SEC CIK: 0001527599
- Website: synlogictx.com

## About

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

## Latest SYBX news and filings

- 2026-11-11 00:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6785615)
- 2026-11-05 13:54 UTC [SEC Form 425] [SEC Form 425 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-synlogic-inc-6775103)
- 2026-11-05 12:00 UTC [Caldera Therapeutics Reports New CLD-423 Phase 1a Data and Expands Immunology and Inflammation Pipeline With Anti IL-17 X TL1A Bispecific Antibody Program](https://www.quantisnow.com/insight/caldera-therapeutics-reports-new-cld-423-phase-1a-data-and-expands-6774414)
- 2026-11-02 13:49 UTC [SEC Form 425] [SEC Form 425 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-synlogic-inc-6766396)
- 2026-11-02 12:00 UTC [Leadership Update] [Caldera Therapeutics Appoints Michelle Doig as Chief Financial Officer and Lee Giguere as Chief Legal Officer](https://www.quantisnow.com/insight/caldera-therapeutics-appoints-michelle-doig-as-chief-financial-officer-and-6765990)
- 2026-08-11 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6676147)
- 2026-07-29 11:25 UTC [SEC Form 425] [SEC Form 425 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-synlogic-inc-6652675)
- 2026-07-29 11:19 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-entry-into-a-material-6652667)
- 2026-07-29 11:00 UTC [Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement](https://www.quantisnow.com/insight/synlogic-and-caldera-therapeutics-announce-merger-agreement-and-concurrent-private-6652590)
- 2026-05-18 14:54 UTC [SEC Form 25-NSE filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-synlogic-inc-6559621)
- 2026-05-14 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6554404)
- 2026-04-30 20:29 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-synlogic-inc-6524847)
- 2026-03-12 20:30 UTC [SEC Form 10-K] [SEC Form 10-K filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-synlogic-inc-6444901)
- 2026-01-29 14:00 UTC [SEC Form 8-K] [Amendment: Synlogic Inc. filed SEC Form 8-K: Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/amendment-synlogic-inc-filed-sec-form-8-k-other-events-notice-6365404)
- 2026-01-20 14:00 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-notice-of-delisting-or-6353564)
- 2025-12-16 01:18 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-leadership-update-submission-of-6317025)
- 2025-11-26 22:25 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-notice-of-delisting-or-6295628)
- 2025-11-13 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6277875)
- 2025-11-13 21:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-synlogic-inc-6277725)
- 2025-11-12 21:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-synlogic-inc-6274916)
- 2025-10-31 19:30 UTC [SEC Form 4] [Officer Dooley Mary Beth sold $284 worth of shares (157 units at $1.81), decreasing direct ownership by 1% to 12,744 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-dooley-mary-beth-sold-284-worth-of-shares-157-6254386)
- 2025-08-21 04:16 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-synlogic-inc-6174171)
- 2025-08-15 20:19 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-synlogic-inc-6168460)
- 2025-08-08 20:01 UTC [SEC Form S-3] [SEC Form S-3 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-synlogic-inc-6156108)
- 2025-08-07 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6154374)
- 2025-05-08 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-6028071)
- 2025-04-30 15:57 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-synlogic-inc-6009738)
- 2025-04-29 20:46 UTC [SEC Form 4] [Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)](https://www.quantisnow.com/insight/director-shea-richard-p-was-granted-15000-shares-increasing-direct-6007818)
- 2025-04-29 20:43 UTC [SEC Form 4] [Director Flynn James P was granted 15,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-flynn-james-p-was-granted-15000-shares-sec-form-6007792)
- 2025-04-03 20:30 UTC [SEC Form 4] [Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-dooley-mary-beth-sold-173-worth-of-shares-144-5975884)
- 2025-03-06 21:47 UTC [SEC Form 10-K] [SEC Form 10-K filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-synlogic-inc-5931480)
- 2025-02-25 21:23 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-synlogic-inc-5908502)
- 2025-02-21 21:30 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-leadership-update-5903082)
- 2025-02-04 22:53 UTC [SEC Form 4] [Officer Dooley Mary Beth sold $2,802 worth of shares (2,107 units at $1.33), decreasing direct ownership by 14% to 13,045 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-dooley-mary-beth-sold-2802-worth-of-shares-2107-5871035)
- 2025-01-14 22:00 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-leadership-update-5845855)
- 2024-12-21 01:40 UTC [SEC Form 8-K] [Synlogic Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/synlogic-inc-filed-sec-form-8-k-leadership-update-5822963)
- 2024-11-14 21:40 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Synlogic Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-synlogic-inc-5776632)
- 2024-11-12 21:49 UTC [SEC Form S-8] [SEC Form S-8 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-synlogic-inc-5768573)
- 2024-11-12 21:47 UTC [SEC Form S-8] [SEC Form S-8 filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-synlogic-inc-5768544)
- 2024-11-12 21:39 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synlogic Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synlogic-inc-5768423)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SYBX
- Earnings history: https://www.quantisnow.com/earnings/SYBX
- Dividend history: https://www.quantisnow.com/dividends/SYBX
- Insider transactions: https://www.quantisnow.com/insiders/SYBX
- Options chain: https://www.quantisnow.com/options/SYBX
- SEC 8-K filings only: https://www.quantisnow.com/company/SYBX/8-k
- RSS and alerts for SYBX: https://www.quantisnow.com/docs/rss-feeds.md
